Webster, Andrew L. H.
Sanders, Mathijs A.
Patel, Krupa
Dietrich, Ralf
Noonan, Raymond J. http://orcid.org/0000-0002-7354-8486
Lach, Francis P.
White, Ryan R.
Goldfarb, Audrey
Hadi, Kevin
Edwards, Matthew M. http://orcid.org/0000-0001-9134-4666
Donovan, Frank X. http://orcid.org/0000-0002-7712-2335
Hoogenboezem, Remco M.
Jung, Moonjung http://orcid.org/0000-0002-1364-1814
Sridhar, Sunandini http://orcid.org/0000-0002-6991-1860
Wiley, Tom F.
Fedrigo, Olivier http://orcid.org/0000-0002-6450-7551
Tian, Huasong
Rosiene, Joel http://orcid.org/0000-0002-8610-370X
Heineman, Thomas
Kennedy, Jennifer A.
Bean, Lorenzo
Rosti, Rasim O.
Tryon, Rebecca
Gonzalez, Ashlyn-Maree
Rosenberg, Allana
Luo, Ji-Dung http://orcid.org/0000-0003-0150-1440
Carroll, Thomas S.
Shroff, Sanjana http://orcid.org/0000-0003-2839-0322
Beaumont, Michael
Velleuer, Eunike http://orcid.org/0000-0003-4328-9556
Rastatter, Jeff C.
Wells, Susanne I. http://orcid.org/0000-0002-7234-676X
Surrallés, Jordi http://orcid.org/0000-0002-4041-7519
Bagby, Grover http://orcid.org/0000-0001-6830-2046
MacMillan, Margaret L. http://orcid.org/0000-0002-0755-0852
Wagner, John E.
Cancio, Maria
Boulad, Farid
Scognamiglio, Theresa
Vaughan, Roger
Beaumont, Kristin G. http://orcid.org/0000-0003-3075-9977
Koren, Amnon http://orcid.org/0000-0002-7144-2602
Imielinski, Marcin http://orcid.org/0000-0002-2211-4741
Chandrasekharappa, Settara C. http://orcid.org/0000-0002-8084-0530
Auerbach, Arleen D. http://orcid.org/0000-0002-6911-8379
Singh, Bhuvanesh
Kutler, David I.
Campbell, Peter J. http://orcid.org/0000-0002-3921-0510
Smogorzewska, Agata http://orcid.org/0000-0001-6285-1562
Article History
Received: 15 August 2021
Accepted: 18 August 2022
First Online: 30 November 2022
Competing interests
: Rocket Pharmaceuticals provided research funding and partial salary support to A.S. for an unrelated project. P.J.C. is a founder, director and consultant for Mu Genomics. B.S. is a co-inventor of intellectual property related to DCN1 small molecule inhibitors licensed by MSK to Cinsanso. He has rights to receive royalty income as a result of this arrangement. MSK has financial interests related to this intellectual property and Cinsanso as a result of this arrangement. The other authors declare no competing interests.